Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro

European Journal of Haematology

Volumn 56, Issue 4, 1996, Pages 213-220

  Petersen, Amarette J ^a   Brown, Ross D ^a   Gibson, John ^a   Pope, Belinda ^a   Luo, Xiao Feng ^a   Schutz, Leonard ^b   Wiley, James S ^c   Joshua, Douglas E ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b KAISER PERMANENTE   (United States)

^c AUSTIN HOSPITAL   (Australia)

Author keywords

Chlorodeoxyadenosine; CLL; Fludarabine; Nucleoside transporter

Indexed keywords

CLADRIBINE; CYTARABINE; FLUDARABINE; NUCLEOSIDE TRANSPORTER PROTEIN; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CYCLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

EID: 0030007561     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb01932.x     Document Type: Article

References (31)

1. ROBERTSON LE, CHUBB S, RAYMOND E, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 1993: 81: 143-150.
2. SPRIGGS D, ROBBINS G, MITCHELL T, KUFE D. Incorporation of 9-β-D-arabinosyl-2-fluoroadenine into HL-60 cellular RNA and DNA. Biochem Pharmacol 1986: 35: 247-252.
3. KEATING MJ, O'BRIEN S, KANTARJIAN H, et al. Nucleoside analogs in the treatment in chronic lymphocytic leukemia. Leuk Lymph 1993: 10: 139-145.
4. JAMIESON GP, BROCKLEBANK AM, SNOOK MB, et al. Flow cytometric quantitation of nucleoside transporter sites on human leukemic cells. Cytometry 1993: 14: 32-38.
5. WILEY JS, JONES SP, SAWYER WH, PATERSON ARP. Cytosine arabinoside influx and nucleoside transporter sites in acute leukemia. J Clin Invest 1982: 69: 479-489.
6. WILEY JS, JONES SP, SAWYER WH. Cytosine arabinoside transport by human leukaemic cells. Eur J Clin Oncol 1983: 19: 1067-1074.
7. 6 - (4 - nitrobenzyl) - 5′- thioadenosine (SAENTA), a novel ligand with high affinity for polypeptides associated with nucleoside transport. J Biochem 1990: 270: 605-614.
8. 2-fluorescein. J Biochem 1991: 273: 667-672.
9. ZINZANI PL, TOSI P, VISANI G, et al. Apoptosis induction with three nucleoside analogs in freshly isolated B-chronic lymphocytic leukemia cells. Am J Hematol 1994: 47: 301-306.
10. PETERSEN AJ, BROWN RD, POPE BB, et al. Multiple myeloma: expression of nucleoside transporters on malignant plasma cells and their relationship to cellular proliferation. Leuk Lymph 1994: 13: 491-499.
11. BROWN RD, POPE B, LUO X-F, GIBSON J, JOSHUA D. The oncoprotein phenotype of plasma cells from patients with multiple myeloma. Leuk Lymph 1994: 16: 147-156.
12. WHITE JC, RATHMELL JP, CAPIZZI RL. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. J Clin Invest 1986: 79: 380-387.
13. WILEY JS, SNOOK MB, JAMIESON GP. Nucleoside transport in acute leukaemia and lymphoma: close relation to proliferative rate. Br J Haematol 1989: 71: 203-207.
14. POWELL BL, WHITE JC, GREGORY BW, et al. S-Phase fraction is not correlated with nucleoside transport in acute myeloid leukaemia cells. Leukemia 1991: 5: 598-601.
15. GHANDI V, NOWAK B, KEATING MJ, PLUNKETT W. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood 1989: 74: 2070-2075.
16. CHESON BD. The purine analogues a therapeutic beauty contest. J Clin Oncol 1992: 10: 352-355.
17. CASS CE, DAHLIG E, LAU EY, LYNCH TP, PATERSON ARP. Fluctuations in nucleoside uptake and binding of the inhibitor of nucleoside transport, nitrobenzyl thioinosine, during the replication cycle of HeLa cells. Cancer Res 1979: 39: 1245-1252.
18. CHEN SF, CLEAVELAND SJ, HOFFMAN AB, WIEMANN MC, PARKS RE, STOECKEER JD. Changes in nucleoside transport sites in acute leukemia. Cancer Res 1986: 46: 3449-3455.
19. WILEY JS, SNOOK MB, JAMIESON GP. A controversy: nucleoside transporter expression is correlated with proliferative rate in acute myeloid leukemia. Leukemia 1992: 6: 486-488.
20. WILEY JS, CEBON JS, JAMIESON GP, et al. Assessment of proliferalive responses to granulocytic-macrophage colony stimulating factor (GM-CSF) in acute myeloid leukaemia using a fluorescent ligand for the nucleoside transporter. Leukemia 1994: 8: 181-185.
21. SMITH CL, PILARSKI LM, EGERTON ML, WILEY JS. Nucleoside transport and proliferative rate in human thymocytes and lymphocytes. Blood 1989: 74: 2038-2042.
22. ANDREEFF M, DARZYNKIEWICZ Z, SHARPLESS TK, CLARKSON BD, MELAMED MR. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 1980: 55: 282-293.
23. SCHENA M, GOTTARDI D, GHIA P, et al. The role of bcl-2 in the pathogenesis of B chronic lymphocytic leukemia. Leuk Lymph 1993: 11: 173-179.
24. SCHENA M, LARSSON LG, GOTTARDI D, et al. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992: 11: 2981-2989.
25. PANAYIOTIDIS P, GANESHAGURLI K, JABHAR SAB, HOFFBRAND AV. Interleukin-4 inhibits apoptotic cell death and loss of bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1993: 85: 439-445.
26. FRANKFURT OS, BYRNFS JJ, SECKINGER D, SUGARBAKER EV. Apoptosis (programmed cell death) and the evaluation of chemosensitivity in chronic lymphocytic leukemia and lymphoma. One Res 1993: 5: 37-42.
27. BISSONETTE RP, ECHEVERRI F, MAHBOUBI A, GREEN DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992: 359: 552-554.
28. FANIDI A, HARRINGTON EA, EVAN GI. Cooperative interaction between c-nyc and bcl-2 proto-oncogenes. Nature 1992: 359: 554-556.
29. LARSSON LG, GRAY HE, TOTTERMAN T, PITTERSSON U, NILSSON K. Drastically increased expression of myc and fos protooncogenes during in vitro differentiation of chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA 1987: 84: 223-227.
30. NUNFZ G, MERINO R, GRILLOT D, GONZALEZ-GARCIA M. Bcl-2 and Bcl-x: regulatory switches for lymphoid death and survival. Immunol Today 1994: 15: 582-587.
31. CARLSSON M, SUNDSTROM C, BENGTSSON M, TOTTERMAN TH, ROSEN A, NILSSON K. Interleukin 4 strongly augments or inhibits DNA synthesis and differentiation of B-type chronic lymphocytic leukemia cells depending on the costimulatory activation and progression signals. Eur J Immunol 1989: 19: 913-921.